---
document_datetime: 2025-12-02 05:27:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/valtropin.html
document_name: valtropin.html
version: success
processing_time: 0.1010355
conversion_datetime: 2025-12-25 10:41:45.546126
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Valtropin

[RSS](/en/individual-human-medicine.xml/67133)

##### Withdrawn

This medicine's authorisation has been withdrawn

somatropin Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Valtropin](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 April 2006 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Valtropin (somatropin), which had been approved for the treatment of children in the following situations:

- children from two years of age and adolescents who fail to grow because they lack growth hormone (replacement therapy);
- children who are short because of Turner syndrome (a rare genetic disorder affecting girls), confirmed by chromosome analysis (DNA testing);
- children before puberty, who fail to grow because of longstanding kidney disease (chronic renal insufficiency).

Valtropin was also approved for the treatment of adults with pronounced growth hormone deficiency, which has started in adulthood or childhood and needs to be confirmed by testing before treatment (replacement therapy). The marketing authorisation holder (MAH) responsible for Valtropin was BioPartners GmbH.

The European Commission was notified by a letter dated 31 October 2011 of the MAH's decision to voluntarily withdraw the marketing authorisation for commercial reasons. Valtropin was not marketed in any EU country. On 10 May 2012 the European Commission issued a decision to withdraw the marketing authorisation for Valtropin.

Pursuant to this decision the European Public Assessment Report for Valtropin is updated to reflect that the marketing authorisation is no longer valid.

Valtropin : EPAR - Summary for the public

English (EN) (293.37 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 14/08/2012

[View](/en/documents/overview/valtropin-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-104)

български (BG) (388.3 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/bg/documents/overview/valtropin-epar-summary-public_bg.pdf)

español (ES) (359.85 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/es/documents/overview/valtropin-epar-summary-public_es.pdf)

čeština (CS) (355.4 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/cs/documents/overview/valtropin-epar-summary-public_cs.pdf)

dansk (DA) (359.15 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/da/documents/overview/valtropin-epar-summary-public_da.pdf)

Deutsch (DE) (359.6 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/de/documents/overview/valtropin-epar-summary-public_de.pdf)

eesti keel (ET) (294.72 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/et/documents/overview/valtropin-epar-summary-public_et.pdf)

ελληνικά (EL) (396.62 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/el/documents/overview/valtropin-epar-summary-public_el.pdf)

français (FR) (359.58 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/fr/documents/overview/valtropin-epar-summary-public_fr.pdf)

italiano (IT) (299.96 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/it/documents/overview/valtropin-epar-summary-public_it.pdf)

latviešu valoda (LV) (361.07 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/lv/documents/overview/valtropin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (325.44 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/lt/documents/overview/valtropin-epar-summary-public_lt.pdf)

magyar (HU) (410.72 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/hu/documents/overview/valtropin-epar-summary-public_hu.pdf)

Malti (MT) (414.74 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/mt/documents/overview/valtropin-epar-summary-public_mt.pdf)

Nederlands (NL) (357.59 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/nl/documents/overview/valtropin-epar-summary-public_nl.pdf)

polski (PL) (416.83 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/pl/documents/overview/valtropin-epar-summary-public_pl.pdf)

português (PT) (359.04 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/pt/documents/overview/valtropin-epar-summary-public_pt.pdf)

română (RO) (386.6 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/ro/documents/overview/valtropin-epar-summary-public_ro.pdf)

slovenčina (SK) (352.94 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/sk/documents/overview/valtropin-epar-summary-public_sk.pdf)

slovenščina (SL) (408.14 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/sl/documents/overview/valtropin-epar-summary-public_sl.pdf)

Suomi (FI) (358.29 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/fi/documents/overview/valtropin-epar-summary-public_fi.pdf)

svenska (SV) (296.11 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

14/08/2012

[View](/sv/documents/overview/valtropin-epar-summary-public_sv.pdf)

## Product information

Valtropin : EPAR - Product Information

English (EN) (559.29 KB - PDF)

**First published:** 17/06/2009

**Last updated:** 14/08/2012

[View](/en/documents/product-information/valtropin-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-197)

български (BG) (1.31 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/bg/documents/product-information/valtropin-epar-product-information_bg.pdf)

español (ES) (579.42 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/es/documents/product-information/valtropin-epar-product-information_es.pdf)

čeština (CS) (1002.54 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/cs/documents/product-information/valtropin-epar-product-information_cs.pdf)

dansk (DA) (575.25 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/da/documents/product-information/valtropin-epar-product-information_da.pdf)

Deutsch (DE) (595.4 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/de/documents/product-information/valtropin-epar-product-information_de.pdf)

eesti keel (ET) (566.73 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/et/documents/product-information/valtropin-epar-product-information_et.pdf)

ελληνικά (EL) (1.4 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/el/documents/product-information/valtropin-epar-product-information_el.pdf)

français (FR) (592.37 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/fr/documents/product-information/valtropin-epar-product-information_fr.pdf)

íslenska (IS) (607.4 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/is/documents/product-information/valtropin-epar-product-information_is.pdf)

italiano (IT) (582.2 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/it/documents/product-information/valtropin-epar-product-information_it.pdf)

latviešu valoda (LV) (1.05 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/lv/documents/product-information/valtropin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (750.5 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/lt/documents/product-information/valtropin-epar-product-information_lt.pdf)

magyar (HU) (990.04 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/hu/documents/product-information/valtropin-epar-product-information_hu.pdf)

Malti (MT) (1 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/mt/documents/product-information/valtropin-epar-product-information_mt.pdf)

Nederlands (NL) (585.79 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/nl/documents/product-information/valtropin-epar-product-information_nl.pdf)

norsk (NO) (608.55 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/no/documents/product-information/valtropin-epar-product-information_no.pdf)

polski (PL) (1.09 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/pl/documents/product-information/valtropin-epar-product-information_pl.pdf)

português (PT) (588.42 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/pt/documents/product-information/valtropin-epar-product-information_pt.pdf)

română (RO) (707.82 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/ro/documents/product-information/valtropin-epar-product-information_ro.pdf)

slovenčina (SK) (1.02 MB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/sk/documents/product-information/valtropin-epar-product-information_sk.pdf)

slovenščina (SL) (953.71 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/sl/documents/product-information/valtropin-epar-product-information_sl.pdf)

Suomi (FI) (575.51 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/fi/documents/product-information/valtropin-epar-product-information_fi.pdf)

svenska (SV) (574.39 KB - PDF)

**First published:**

17/06/2009

**Last updated:**

14/08/2012

[View](/sv/documents/product-information/valtropin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A20/08 10/05/2012

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Valtropin : EPAR - All Authorised presentations

English (EN) (237.13 KB - PDF)

**First published:** 27/08/2008

**Last updated:** 14/08/2012

[View](/en/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-205)

español (ES) (237.24 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/es/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (312.34 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/cs/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (237.02 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/da/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (237.32 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/de/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (237.25 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/et/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (313.85 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/el/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_el.pdf)

français (FR) (237.52 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/fr/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (237.15 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/it/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (313.78 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/lv/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (266.54 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/lt/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (310.74 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/hu/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (238.55 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/nl/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_nl.pdf)

polski (PL) (315.61 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/pl/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_pl.pdf)

português (PT) (237.17 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/pt/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (313.41 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/sk/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (280.13 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/sl/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (236.8 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/fi/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (237.21 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

14/08/2012

[View](/sv/documents/all-authorised-presentations/valtropin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Valtropin Active substance somatropin International non-proprietary name (INN) or common name somatropin Therapeutic area (MeSH)

- Turner Syndrome
- Dwarfism, Pituitary

Anatomical therapeutic chemical (ATC) code H01AC01

### Pharmacotherapeutic group

Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

**Paediatric poulation**

- Long-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with growth failure due to an inadequate secretion of normal endogenous growth hormone.
- Treatment of short stature in children with Turner syndrome, confirmed by chromosome analysis.
- Treatment of growth retardation in pre-pubertal children with chronic renal insufficiency.

**Adult patients**

- Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology.

Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (&lt; 2 standard deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

## Authorisation details

EMA product number EMEA/H/C/000602

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

BioPartners GmbH

Kaiserpassage 11

Marketing authorisation issued 24/04/2006 Withdrawal of marketing authorisation 10/05/2012 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Valtropin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (294.2 KB - PDF)

**First published:** 17/06/2009

**Last updated:** 14/08/2012

[View](/en/documents/procedural-steps-after/valtropin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Valtropin-H-C-620-A20-08 : EPAR - Assessment Report - Variation

Adopted

English (EN) (452.2 KB - PDF)

**First published:** 03/08/2012

**Last updated:** 14/08/2012

[View](/en/documents/variation-report/valtropin-h-c-620-a20-08-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Valtropin : EPAR - Procedural steps taken before authorisation

English (EN) (250.7 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 14/08/2012

[View](/en/documents/procedural-steps/valtropin-epar-procedural-steps-taken-authorisation_en.pdf)

Valtropin : EPAR - Scientific Discussion

English (EN) (576.64 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 14/08/2012

[View](/en/documents/scientific-discussion/valtropin-epar-scientific-discussion_en.pdf)

#### News on Valtropin

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2011) 16/12/2011

**This page was last updated on** 14/08/2012

## Share this page

[Back to top](#main-content)